AVXL (Anavex Life Sciences) ROCE %: -24.50% (As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.56
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences ROCE %?

Anavex Life Sciences AVXL -0.97% 30 ROCE % is -24.50% as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anavex Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2025 was -24.50%.

Anavex Life Sciences  (NAS:AVXL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anavex Life Sciences ROCE % Related Terms

Anavex Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences ROCE % Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.28 -32.47 -32.74 -32.81 -43.11

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.99 -47.15 -60.01 -27.92 -24.50
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences ROCE % Calculation

Anavex Life Sciences's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-46.377/( ( (135.567 - 15.304) + (103.815 - 8.946) )/ 2 )
=-46.377/( (120.263+94.869)/ 2 )
=-46.377/107.566
=-43.11 %

Anavex Life Sciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-27.128/( ( (103.815 - 8.946) + (132.989 - 6.371) )/ 2 )
=-27.128/( ( 94.869 + 126.618 )/ 2 )
=-27.128/110.7435
=-24.50 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -24.50% mean?
Anavex Life Sciences (AVXL) has a ROCE % of -24.50% as of Dec. 2025.
Is Anavex Life Sciences' ROCE % too high?
Anavex Life Sciences' current ROCE % is -24.50%. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' ROCE % compare to ZNTL and HUMA?
Anavex Life Sciences' ROCE % of -24.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Anavex Life Sciences's current ROCE % is -24.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current ROCE % of -24.50%. The current ROCE % is -24.50%. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current ROCE % is -24.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price